Recipharm and CTC Clinical Trial Consultants partnered in 2017 to form Recipharma Pathway to Clinic, an integrated service that offers a streamlined pathway to first-in-human milestones. As part of the solution, Recipharm performs formulation development and GMP clinical supply manufacture, whilst CTC Clinical Trial Consultants is responsible for early phase clinical trials (Phase 0–IIa).
The GLP bioanalysis laboratory will now continue its assignments as a newly formed company, Lablytica Life Science AB, 100% owned by CTR.
The analytical activities will continue without interruption with the same staff, in the same facilities, using the same instrumentation and most importantly, the same validated analytical methods. David Pekar, Head of Bioanalysis, will continue to lead the team.
Maria Lundberg, vice president of Global Analytical Development at Recipharm said, “We are pleased to announce this divestment which allows us to focus on delivering a comprehensive offering from medicinal chemistry through to commercial API manufacturing. This step also further improves the Recipharm Pathway to Clinic offering, where Recipharm continues to facilitate clinical trials by developing and supplying the clinical trial material. The GLP laboratory will now operate within the same group as CTC Clinical Trial Consultants which is a far more logical approach and will result in the even more efficient conduct of clinical trials ultimately improving the result for our customers.”
Bengt Dahlström, Chairman of the Board at CTR said, “Through the formation of Lablytica as a sister company to CTC Clinical Trial Consultants we believe we will be able to offer a more integrated approach and develop the services for our customers using the talented staff and facilities in the GLP bioanalysis business. The partnership with Recipharm provides a complete solution for first-in-human projects.”